Sionna Therapeutics (SION) | Stock Overview & Key Data
Sionna Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $22.35
High: $24.29
on September 5, 2025
52 Week Range
Low: $7.26
High: $26.50
on April 11, 2025
on August 28, 2025
All-Time High: $26.50 on August 28, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.1B
EPS
-1.72
P/E Ratio (TTM)
-16.51
Forward P/E
-11.58
P/B Ratio
3.15
PEG Ratio
4.35
Div. Yield
N/A
ROE
37.68%
Beta
N/A
Debt to Equity
2.75
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-33.21%
Return on Equity (TTM)
37.68%
EBITDA
$-87.0M
Net Income (TTM)
$-75.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sionna Therapeutics SION | 1.12B Small-cap | -2.52% | 36.91% | 49.72% | 45.63% | -4.00% | -4.00% | -4.00% | -4.00% |
| Vertex VRTX | 101.56B Large-cap | 1.30% | 5.63% | -10.75% | -19.43% | -2.38% | -15.36% | 35.61% | 53.56% |
| Regeneron REGN | 60.77B Large-cap | -1.26% | 0.61% | 18.70% | -16.56% | -19.83% | -49.33% | -20.84% | 5.26% |
| Adaptive ADPT | 1.98B Small-cap | -2.50% | 16.29% | 30.19% | 60.02% | 107.59% | 200.94% | 44.22% | -68.06% |
| Arcutis ARQT | 1.94B Small-cap | 10.50% | 11.95% | 26.94% | 16.04% | 17.79% | 65.54% | -16.05% | -26.83% |
| Travere Therapeutics TVTX | 1.93B Small-cap | 23.71% | 29.80% | 47.08% | 11.54% | 14.13% | 97.09% | -20.82% | 16.91% |
Ownership & Short Interest
Insider Ownership
7.01%
Institutional Ownership
97.94%
Shares Short
4M
Short Ratio
22.40
Short % of Shares Outstanding
13.71%
Average 10-Day Volume
229K
Average 90-Day Volume
194K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SION's 52-week high and low?
- In the last 52 weeks, Sionna Therapeutics reached a high of $26.50 (on August 28, 2025) and a low of $7.26 (on April 11, 2025).
- What is the market cap and P/E ratio for SION?
- Curious about Sionna Therapeutics's size and valuation? Its market capitalization stands at 1.12B. When it comes to valuation, the P/E ratio (trailing twelve months) is -16.51, and the forward P/E (looking ahead) is -11.58.
- Does SION pay dividends? If so, what's the yield?
- As for dividends, Sionna Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sionna Therapeutics's main competitors or similar companies to consider before investing?
When looking at Sionna Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.56B Healthcare Biotechnology -15.36% 35.61% Regeneron
REGN60.77B Healthcare Biotechnology -49.33% -20.84% Adaptive
ADPT1.98B Healthcare Biotechnology 200.94% 44.22% Arcutis
ARQT1.94B Healthcare Biotechnology 65.54% -16.05% Travere Therapeutics
TVTX1.93B Healthcare Biotechnology 97.09% -20.82% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sionna Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Sionna Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 37.68%, the Debt to Equity ratio from the most recent quarter is 2.75, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for SION?
- Looking at Sionna Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of SION stock is held by insiders and institutions?
- Wondering who owns Sionna Therapeutics stock? Company insiders (like executives and directors) hold about 7.01% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 97.94%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.